Belatacept

N/A

Report date: 2026/05/12 20:00:17
First In Class

Base Information

Drug NameBelatacept
Drug Alias Name贝他西普belataceptumbelatacept贝拉西普CTLA4-IgLEA29Y +[10] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCluster of differentiation 86 inhibitorsCluster of differentiation 80 inhibitors
TargetsCluster of differentiation 80Cluster of differentiation 86
Therapy Area/IndicationsRejection of organ transplantationRejection of renal transplantationPancreatic neuroendocrine tumors (pNET) +[10] 
Global Approved IndicationsRejection of renal transplantation
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2011/06/15
Country/TerritoryBelgiumCanadaUnited States +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyNantes University HospitalBristol-Myers Squibb Pharma Eeig +[4] 
Inactive CompaniesUniversity Of California San FranciscoThe Brigham and Women's HospitalThe University Of Chicago +[5] 
Active IndicationsRejection of renal transplantationKidney Failure, ChronicRejection in heart transplantation
Inactive IndicationsRejection of organ transplantationPancreatic neuroendocrine tumors (pNET)Graft Rejection +[7] 

Other Information

ATC CodeL04AA28
Related LinksWikipediaDrugBankKEGG